ZYMOGENETICS INC

SEATTLE, WA · Still private

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Headquarters: SEATTLE, WA
Latest Form D: $15.5M, Nov 2008
Total capital: $18.2M

Federal grants: $2.6M; 17 awards · 1984–1990
Private capital raised: $15.5M; 1 Form D · last Nov 2008; 215 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 19; 21 pending · first 2017

Capital timeline

Latest events

Nov 2008Private capital raisedForm D · SEC · 1st filing$15.5M
Jun 1990Federal grantHealth and Human S · R01 · Molecular Dissection Of A Chromosomal Fragile Site$183K
Jun 1990Federal grantHealth and Human S · R01 · Molecular Dissection Of A Chromosomal Fragile Site$127K
Jun 1990Federal grantHealth and Human S · R01 · Molecular Dissection Of A Chromosomal Fragile Site$127K
Sep 1987Federal grantHealth and Human S · Phase II · Human Granulocyte-macrophage Colony Stimulating Factor$250K
Sep 1987Federal grantHealth and Human S · Phase II · Human Granulocyte-macrophage Colony Stimulating Factor$250K
Aug 1987Federal grantHealth and Human S · Phase I · Cloning/sequencing/expression Of Human Bsa Lipase Cdna$50K

Show 11 earlier federal awards

Jul 1987Federal grantHealth and Human S · Phase II · Expression Of Human Protein C In Mammalian Cells$279K
Jul 1987Federal grantHealth and Human S · Phase II · Expression Of Human Protein C In Mammalian Cells$221K
Jan 1987Federal grantHealth and Human S · Phase I · Cloning And Expression Of Human INTERLEUKIN-3$50K
Apr 1986Federal grantHealth and Human S · Phase I · Expression Of Human Protein C In Mammalian Cells$50K
Apr 1986Federal grantHealth and Human S · Phase I · Cloning And Expression Of A Human Antibody For Anthrax E$50K
Sep 1985Federal grantHealth and Human S · Phase I · Cloning And Expressing Human Colony Stimulating Factor$50K
May 1985Federal grantHealth and Human S · Phase I · Antibody Production With Trace Quantities Of Proteins$50K
Sep 1984Federal grantHealth and Human S · R01 · Replication Function Of Saccharomyces Cerevesiae$201K
Sep 1984Federal grantHealth and Human S · R01 · Histone-dna Interactions In Chromatin Replication$324K
Sep 1984Federal grantHealth and Human S · R01 · Replication Function Of Saccharomyces Cerevesiae$173K
Sep 1984Federal grantHealth and Human S · R01 · Replication Function Of Saccharomyces Cerevesiae$214K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

291months

from ZYMOGENETICS INC’s first federal award to its first private round.

First federal award · Sep 1984: Health and Human S · $214K
First Form D · Nov 2008: $15.5M · 1st Form D
Awards before first raise: 17 awards

An association in public records, not a cause or a prediction.

Founders and team

From SEC Form D filings

Bruce L.A. Carter, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
Darren R. HambyExecutive OfficerNamed in SEC Form D filings
David I. Hirsch, Ph.D.DirectorNamed in SEC Form D filings
David H. MacCallumDirectorNamed in SEC Form D filings
Douglas E. Williams, Ph.D.Executive OfficerNamed in SEC Form D filings
Edward E. Penhoet, Ph.D.DirectorNamed in SEC Form D filings

Show all 17 people

Heather L. FranklinExecutive OfficerNamed in SEC Form D filings
James A. HarperDirectorNamed in SEC Form D filings
James A. JohnsonExecutive OfficerNamed in SEC Form D filings
Jonathan S. LeffDirectorNamed in SEC Form D filings
Judith A. Hemberger, Ph.D.DirectorNamed in SEC Form D filings
Kurt Anker NielsenDirectorNamed in SEC Form D filings
Lars Rebien SorensenDirectorNamed in SEC Form D filings
Michael J. DwyerExecutive OfficerNamed in SEC Form D filings
Nicole Onetto, M.D.Executive OfficerNamed in SEC Form D filings
Suzanne M. Shema, J.D.Executive OfficerNamed in SEC Form D filings
Vaughn B. Himes, Ph.D.Executive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 19 granted of 40

Sep 25, 2025PendingCompositions And Methods For Modulating Immune ResponsesUSPTOApplication 19031067
Apr 26, 2022GrantedMethods Of Treating Prurigo Nodularis Using ANTI-IL-31RA Antibody CompositionsUSPTOUS 11,312,779
Jan 6, 2022PendingCompositions And Methods For Modulating Immune ResponsesUSPTOApplication 17483262

Show all 40 patent records

Compositions And Methods For Modulating Immune ResponsesSep 25, 2025 · Application 19031067Pending
Methods Of Treating Prurigo Nodularis Using ANTI-IL-31RA Antibody CompositionsApr 26, 2022 · US 11,312,779Granted
Compositions And Methods For Modulating Immune ResponsesJan 6, 2022 · Application 17483262Pending
Levels Of Bcma Protein Expression On B Cells And Use In Diagnostic Methods Of Treating Systemic Lupus ErythematosusMay 13, 2021 · Application 17115326Pending
Use Of IL-17A And IL-17F Cross-reactive Monoclonal Antibodies For Treating Inflammatory DiseasesMay 5, 2020 · US 10,640,575Granted
Treating Inflammation With Soluble Hybrid Fcgamma ReceptorsApr 30, 2020 · Application 16737039Pending
Methods Of Treating Skin Disorders Using ANTI-IL-31RA AntibodiesApr 7, 2020 · US 10,611,846Granted
Soluble Hybrid Fcgamma Receptors And Related MethodsFeb 25, 2020 · US 10,570,187Granted
Treating Inflammation With IL-17/IL-23 Bispecific AntibodiesFeb 18, 2020 · US 10,562,967Granted
Compositions And Methods For Modulating Immune ResponsesDec 12, 2019 · Application 16540819Pending
Use Of IL-31 Monoclonal Antibodies For Treating Prurigo NodularisDec 12, 2019 · Application 16548584Pending
IL-31 Antibody CompositionsNov 7, 2019 · Application 16144289Pending
Use Of IL-31 Monoclonal Antibodies For Treating PruritusOct 8, 2019 · US 10,434,173Granted
Polynucleotides Encoding IL-31 Monoclonal AntibodiesMay 16, 2019 · Application 16255919Pending
Use Of IL-31 Monoclonal Antibodies For Reducing PruritusApr 30, 2019 · US 10,273,297Granted
Use Of IL-31 Monoclonal Antibodies For Antagonizing Signal Transduction In Dorsal Root Ganglion CellsApr 25, 2019 · Application 16227266Pending
Use Of IL-31RA Monoclonal Antibodies For Antagonizing Signal Transduction In Dorsal Root Ganglion CellsApr 18, 2019 · Application 16227307Pending
Methods Of Treating Atopic Dermatitis With IL-31 Monoclonal AntibodiesApr 16, 2019 · US 10,259,868Granted
Methods Of Producing A ZCYTOR17 Heterodimeric Cytokine ReceptorMar 12, 2019 · US 10,227,415Granted
ZCYTOR17 Heterodimeric Cytokine Receptor Monoclonal AntibodiesDec 6, 2018 · Application 16100485Pending
B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODSSep 13, 2018 · Application 15987969Pending
Polynucleotides Encoding Monoclonal Antibodies That Bind Both IL-17A And IL-17FSep 6, 2018 · Application 15980325Pending
Compositions And Methods For Modulating Immune ResponsesSep 6, 2018 · Application 15973000Pending
Methods Of Treating Inflammation Using IL-17A And IL-17F Cross-reactive Monoclonal AntibodiesJul 17, 2018 · US 10,023,656Granted
B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODSJun 26, 2018 · US 10,005,837Granted
Monoclonal Antibodies That Bind Both IL-17A And IL-17FJun 19, 2018 · US 10,000,563Granted
Method of treating CD155 expressing cancersJun 12, 2018 · US 9,994,637Granted
Use Of An IL-17/IL-23 Bispecific Antibody For Treating InflammationJun 12, 2018 · US 9,994,634Granted
IL-31 Antibody CompositionsJun 7, 2018 · Application 15429750Pending
Methods Of Treating Skin Disorders Using ANTI-IL-31RA AntibodiesApr 5, 2018 · Application 15839362Pending
Use Of IL-31 Monoclonal Antibodies For Antagonizing Signal Transduction In Dorsal Root Ganglion CellsMar 8, 2018 · Application 15800980Pending
Use Of IL-31RA Monoclonal Antibodies For Antagonizing Signal Transduction In Dorsal Root Ganglion CellsFeb 15, 2018 · Application 15799445Pending
Methods Of Treating Atopic Dermatitis With IL-31 Monoclonal AntibodiesJan 30, 2018 · US 9,878,038Granted
ZCYTOR17 Heterodimeric Cytokine Receptor Monoclonal AntibodiesDec 28, 2017 · Application 15701214Pending
Use Of IL-31 Monoclonal Antibodies For Treating Neuronal InflammationDec 5, 2017 · US 9,834,602Granted
Use Of IL-31RA Monoclonal Antibodies For Treating Neuronal InflammationNov 28, 2017 · US 9,828,431Granted
Method Of Reducing Pruritus Using IL-31 Monoclonal AntibodiesNov 21, 2017 · US 9,822,177Granted
Methods Of Treating Skin Disorders Using ANTI-IL-31RA AntibodiesSep 28, 2017 · Application 15615567Pending
Homogeneous Preparations Of IL-31Sep 28, 2017 · Application 15615615Pending
ZCYTOR17 Heterodimeric Cytokine ReceptorAug 22, 2017 · US 9,738,700Granted

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.